Dr. Aloke Finn, interventional cardiologist and researcher in the area of blood biomaterials, shares his research and catches you up on the latest data for short-term dual anti-platelet therapy (DAPT) in High Bleeding Risk (HBR) patients, including which stent types are ideally suited to DAPT.
Learn the definitions and prevalence of HBR patients
Patient considerations when implanting a stent
Cellular-level interactions when implanting a stent
Stent options for HBR and short-DAPT patients
What does XIENCE 28 & 90 tell us about short-DAPT patients?
Patient-scoring using ARC definitions of HBR patients
Stent options with real-world HBR patients
Patient questions that should be answered prior to implanting a stent
MAT-2211924 v1.0
STAY CONNECTED